Farxiga Weight Loss

 

Generic name: Dapagliflozin (Oral route)
Drug class: SGLT-2 inhibitors

Therapeutic Class: Hypoglycemic

Pharmacologic Class: Sodium-Glucose Co-Transporter 2 Inhibitor

 

Overview of Farxiga Weight Loss

Farxiga Weight Loss
Farxiga

Farxiga weight loss can happen with Farxiga alone or in combination with other diabetic medications. Farxiga can lead to moderate weight loss, though it’s not a weight-loss medication. Studies have shown that people who took Farxiga on its own, either 5 – or 10-mg per day lost around 6 pounds in 24 weeks. Research also found that the average weight loss for those who took Farxiga in conjunction with metformin, a different type 2 diabetes medication, was 7 to 6-7 pounds over the course of 24 weeks.

Farxiga has been approved by U.S. Food and Drug Administration to treat type 2 diabetes as well as heart failure and chronic kidney condition. But, numerous studies have demonstrated that a beneficial side effect from taking Farxiga could be a small weight reduction. This could occur with Farxiga as a stand-alone drug or when it’s combined with another diabetes medication such as glucose or some other orally administered diabetes medications.

Farxiga is part of a group of drugs called sodium-glucose-cotransporter-2 (SGLT2) inhibitors. The drugs prevent the kidneys from taking in excess sugar that is in your blood. The substances are eliminated through urine. This could result in you urinating more frequently and dehydrating. To combat this Your doctor might suggest drinking more fluids than usual while taking Farxiga.

The manufacturer also suggests that patients taking Farxiga follow nutritious meals and participate in regular exercise.

Farxiga Weight Loss alone,  or in combination with other drugs

 

Farxiga 10 mg monotherapy

Farxiga 10 mg taken as monotherapy also produced significantly improved fasting plasma glucose (FPG) as well as significantly reduced body weight as compared to metformin by itself and was comparable to metformin the monotherapy XR in reducing HbA1c.

Initial Combination Therapy using Metformin XR

The treatment combination comprised of Farxiga 10 mg and metformin XR showed statistically significant improvement on HbA1c as well as fasting plasma glucose (FPG) in comparison to any or both of the monotherapy treatments. There was also a statistically significant reduction in body weight, compared to metformin XR by itself.

The treatment combination comprised of Farxiga 5 mg and metformin XR produced statistically significant improvement of HbA1c and FPG when compared to any one of the monotherapy options and a statistically significant decrease in body weight when compared to metformin XR on its own

In addition to metformin Farxiga, 10 mg showed statistically substantial improvements to HbA1c levels and FPG. It also provided significantly reduced body weight when compared to placebo in Week 24.

 

Active Glipizide-Controlled Study Add-On to Metformin

Farxiga treatment resulted in a statistically significant reduction in body weight at Week 52, compared to an increase in body weight for the group treated with glipizide.

Add-On Combination Therapy that includes a Sulfonylurea

When combined with glimepiride Farxiga 10 mg produced significant statistical improvement in HbA1c, FPG, and PPG after 2 hours, as well as statistically significant reductions in body weight as compared to placebo and glimepiride during Week 24.

Add-On Combination Therapy using a Thiazolidinedione

When combined with pioglitazone the treatment of Farxiga 10 mg produced significant statistical improvements in HbA1c, the 2-hour PPG, FPG, and the percentage of patients who achieve HbA1c less than 7%, and a statistically significant decrease in body weight as compared to the pioglitazone and placebo groups.

Add-On Combination Therapy Therapy using Insulin

In Week 24 Farxiga dosage of 10 mg produced significant improvement in HbA1c levels and a decrease in the mean dose of insulin, as well as a statistically significant reduction in body weight as compared to placebo when used in conjunction with insulin, or without the addition of two medications.

 

Additional details

Always consult your doctor to confirm that the information provided on this page is applicable to your specific situation.

One Response

Leave a Reply